ResearchFocus on the pharmaceutical and biotech industry
- Overview of Savara Pharmaceutical’s Clinical Trial Programs
Rob Neville of Savara Pharmaceuticals provides an overview of his company’s Molgradex (for PAP and NTM lung infection) and AeroVanc (an inhaled formulation of vancomycin, for the treatment of persistent methicillin-resistant Staphylococcus aureus, or MRSA, lung infection in cystic fibrosis)
- Dr. John Maraganore of Alnylam Highlights the Importance of Diversity
Dr. John Maraganore, CEO of Alnylam highlights the importance of diversity. Maraganore has led a career pursuing therapies to address unmet medical needs. He is helping lead the development of RNAi therapeutics which aim to address genetic medicines, cardio-metabolic diseases and hepatic infectious diseases.
- Neurotrope BioSciences’ Upcoming Milestones in Fragile X Disease
https://www.youtube.com/watch?v=n0PMCbtU_o8 Dr. Daniel Alkon of Neurotrope BioSciences discusses some of his company’s upcoming milestones, including starting a clinical trial for Fragile X. Dr. Alkon also discusses his comapy’s mechanistic appr …
- Jan-Anders Karlsson on Working with the Cystic Fibrosis Trust
https://www.youtube.com/watch?v=Ls0lzSOuhIM Jan-Anders Karlsson discusses Verona Pharma’s lead candidate, RPL554, as a potential therapy for cystic fibrosis (CF) patients and his company’s work with theCystic Fibrosis Trust. The Cystic Fibrosis …
- Chris Garabedian Discusses His Time at Sarepta
https://www.youtube.com/watch?v=G04-Wdwe76s Chris Garabedian looks back to his time at Sarepta and his legacy there.
- Jan-Anders Karlsson Discusses Verona Pharma’s Clinical Trials for Cystic Fibrosis
https://www.youtube.com/watch?v=Sid3BGs7EEU&t=19s Jan-Anders Karlsson discusses Verona Pharma’s lead candidate, RPL554, as a potential therapy for cystic fibrosis (CF). Verona Pharma is currently undertaking a comprehensive Phase 2 clinical trial p …
- Overview of AzurRx Clinical Trials and Milestones for 2018
https://www.youtube.com/watch?v=xdBplQ9Hyis Thijs Spoor, President of AzurRx, provides an overview of his company’s clinical trial programs, including some key milestones for 2018.
- Cambridge BioMarketing Overview
https://www.youtube.com/watch?v=vbkJ4dd5Apw Shauna Horvath, Director of Strategic Planning at Cambridge BioMarketing, discusses how Cambridge BioMarketing has evolved over the past 15 years to focus exclusively on rare diseases.
- Corbus Pharmaceuticals Overview
https://www.youtube.com/watch?v=9vU-cuiPj90 Yuval Cohen, PhD, CEO of Corbus Pharmaceuticals provides a compnay overview focusing on Lenabasum, a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibr …
- Savara Pharmaceutical’s Cystic Fibrosis Program
https://www.youtube.com/watch?v=FbXLvYjrd_4 Rob Neville of Savara Pharmaceuticals discusses his company’s cystic fibrosis program. Savara initiated its pivotal Phase 3 AVAIL Study of AeroVanc for the treatment of MRSA in Cystic Fibrosis patients …